Trial of Gene Editing Therapy – Potential SCD Cure – Now Recruiting

Trial of Gene Editing Therapy – Potential SCD Cure – Now Recruiting

309907

Trial of Gene Editing Therapy – Potential SCD Cure – Now Recruiting

GPH101, Graphite Bio’s investigational gene editing therapy, is able to correct the disease-causing mutation in blood stem cells of people with sickle cell disease (SCD), new preclinical data shows. Graphite also announced it remains on track to start enrolling participants in a Phase 1/2 trial testing the gene editing therapy in SCD patients before the end of the year. That will make GPH101 the first potentially curative treatment for SCD to be tested in such…

You must be logged in to read/download the full post.